GlassScriptPhysician profile
Seung Yoon Lee
NPI 1649567835
$22,307.46
in general payments reported to CMS, 2019-2025
20 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $1,000 · 2021: $1,673 · 2022: $687 · 2023: $1,225 · 2024: $1,542 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $4,511 · Travel and Lodging: $1,459 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,150.00 |
| Food and Beverage | $4,511.29 |
| Travel and Lodging | $1,458.62 |
| Education | $213.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14,611.87 | 2022-2025 | Uplizna, Enbrel, Otezla |
| Horizon Therapeutics Plc | $2,812.89 | 2020-2022 | |
| Abbvie INC. | $1,332.96 | 2019-2025 | |
| Janssen Biotech, INC. | $915.30 | 2022-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $689.88 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $548.29 | 2022-2025 | |
| Samsung Bioepis Co., LTD. | $500.00 | 2019 | |
| Pfizer INC. | $345.06 | 2022-2024 | |
| Lilly USA, LLC | $115.68 | 2022-2025 | Taltz, Olumiant |
| Astrazeneca Pharmaceuticals LP | $112.44 | 2022-2024 | Saphnelo |
| Glaxosmithkline, LLC. | $61.11 | 2022-2024 | Benlysta, Nucala |
| Genentech USA, INC. | $55.58 | 2024-2025 | Actemra, Ocrevus Zunovo |
| Fresenius Kabi USA, LLC | $52.20 | 2023 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $34.61 | 2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.33 | 2023-2024 | Cyltezo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.18 | 2024 | |
| Sandoz INC. | $19.90 | 2023 | |
| Sobi, INC | $17.09 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $16.77 | 2022 | |
| Mylan Institutional INC. | $14.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seung Yoon Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.